Andrew Wood graduated in Natural Sciences (Cambridge) and Clinical Medicine (Oxford University Medical School) and joined Eli Lilly and Co. following 10 years in academic medicine.

In the pharmaceutical industry Andrew has 18 years experience of clinical development and registration of new molecules - initially in relation to neurological and psychiatric disorders, and has subsequently managed both clinical and preclinical discovery organisations across multiple therapeutic areas in Europe and in Asia.  Latterly he has been leader of Lilly’s inlicensing/business development organisation in Europe and has extensive experience of evaluating drug and technology development projects and of structuring collaborations with external scientists in the biotechnology sector and in academia. 

Andrew retired from Eli Lilly in February 2010 and now works as an independent consultant to the pharma and biotech sectors.